Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

PLoS ONE, Journal Year: 2021, Volume and Issue: 16(2), P. e0244180 - e0244180

Published: Feb. 5, 2021

In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for detection and assessment cognitive decline in mild impairment (MCI) Alzheimer’s disease (AD). Neurophysiological AD derived from FDG-PET, once characterized validated, would expand set existing diagnostic molecular pathology with associated progression neural dysfunction. Since symptoms often begin to appear later life, successful identification EEG-based must account age-related neurophysiological changes that occur even healthy individuals. To end, collected data individuals (n = 26), MCI 53), cognitively normal controls stratified by age into three groups: 18–40 129), 40–60 62) 60–90 (= 55) years old. For each participant, computed power spectral density at channel coherence between pairs channels. Compared matched controls, group, found increases both slower frequencies (Delta, Theta). A smaller but significant increase slow was observed localized temporal areas. These effects on frequency opposed aging a decrease our control groups. The group showed Alpha band consistent same effect aging. However, did not show any change band. Overall, Theta ratio (TAR) provided largest most differences controls. remained small localized. We proposed novel method quantify these bands’ using empirically distributions across time domain averaging time. defined Power Distribution Distance Measure (PDDM) distance measure probability distribution functions (pdf) power. average TAR, PDDF enhanced statistical significance, size, spatial group. designed classifiers differentiating individual participants age-matched classification performance measured area under ROC curve after cross-validation were AUC 0.85 0.6, classifiers, respectively. Posterior AD, PDDM all significantly correlated MMSE score neuropsychological tests

Language: Английский

---

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

Alzheimer s & Dementia, Journal Year: 2021, Volume and Issue: 17(9), P. 1528 - 1553

Published: April 15, 2021

Abstract The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment dementia showed abnormalities in peak frequency, power, “interrelatedness” at posterior alpha (8‐12 Hz) widespread delta (< 4 theta (4‐8 rhythms relation to progression interventions. following consensus statements were subscribed: (1) Standardization of instructions patients, resting state EEG (rsEEG) recording methods, selection artifact‐free rsEEG periods are needed; (2) power density (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) delta, theta, frequency bands may be use stratification monitoring intervention; (3) international multisectoral initiatives mandatory regulatory purposes.

Language: Английский

---

Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer’s disease

eLife, Journal Year: 2022, Volume and Issue: 11

Published: May 26, 2022

Neuronal- and circuit-level abnormalities of excitation inhibition are shown to be associated with tau amyloid-beta (Aβ) in preclinical models Alzheimer's disease (AD). These relationships remain poorly understood patients AD.Using empirical spectra from magnetoencephalography computational modeling (neural mass model), we examined excitatory inhibitory parameters neuronal subpopulations investigated their specific associations regional Aβ, measured by positron emission tomography, AD.Patients AD showed abnormal time-constants neural gains compared age-matched controls. Increased distinctly correlated higher depositions while increased Aβ depositions.Our results provide critical insights about potential mechanistic links between oscillations cellular correlates impaired synaptic functions AD.This study was supported the National Institutes Health grants: K08AG058749 (KGR), F32AG050434-01A1 K23 AG038357 (KAV), P50 AG023501, P01 AG19724 (BLM), P50-AG023501 (BLM GDR), R01 AG045611 (GDR); AG034570, AG062542 (WJ); NS100440 (SSN), DC176960 DC017091 AG062196 (SSN); a grant John Douglas French Foundation (KAV); grants Larry L. Hillblom Foundation: 2015-A-034-FEL 2019-A-013-SUP (KGR); Association: AARG-21-849773 PCTRB-13-288476 made possible Part CloudTM (ETAC-09-133596); Tau Consortium (GDR WJJ), gift S. D. Bechtel Jr. Foundation.

Language: Английский

---

The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

Biomolecules, Journal Year: 2023, Volume and Issue: 13(3), P. 453 - 453

Published: March 1, 2023

Old age increases the risk of Alzheimer’s disease (AD), most common neurodegenerative disease, a devastating disorder human mind and leading cause dementia. Worldwide, 50 million people have it is estimated that there will be 150 by 2050. Today, healthcare for AD patients consumes 1% global economy. According to amyloid cascade hypothesis, begins in brain accumulating aggregating Aβ peptides forming β-amyloid fibrils (Aβ42). However, clinical trials, reducing peptide production formation did not slow cognitive decline or improve daily life patients. Prevention studies cognitively unimpaired at high genetically destined develop also slowed decline. These observations argue against hypothesis etiology, its development, mechanisms. Here, we look other avenues research AD, such as presenilin synaptic glutamate signaling, role astrocytes transporter EAAT2 development AD.

Language: Английский

---

Virtual brain twins: from basic neuroscience to clinical use

National Science Review, Journal Year: 2024, Volume and Issue: 11(5)

Published: Feb. 27, 2024

ABSTRACT Virtual brain twins are personalized, generative and adaptive models based on data from an individual’s for scientific clinical use. After a description of the key elements virtual twins, we present standard model personalized whole-brain network models. The personalization is accomplished using subject’s imaging by three means: (1) assemble cortical subcortical areas in subject-specific space; (2) directly map connectivity into models, which can be generalized to other parameters; (3) estimate relevant parameters through inversion, typically probabilistic machine learning. We use healthy ageing five diseases: epilepsy, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease psychiatric disorders. Specifically, introduce spatial masks demonstrate their physiological pathophysiological hypotheses. Finally, pinpoint challenges future directions.

Language: Английский

---

Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults

Nature Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 18, 2024

Language: Английский

---

Complexity of EEG Dynamics for Early Diagnosis of Alzheimer's Disease Using Permutation Entropy Neuromarker

Computer Methods and Programs in Biomedicine, Journal Year: 2021, Volume and Issue: 206, P. 106116 - 106116

Published: April 16, 2021

Language: Английский

---

Developments in scalable strategies for detecting early markers of cognitive decline

Translational Psychiatry, Journal Year: 2022, Volume and Issue: 12(1)

Published: Nov. 9, 2022

Abstract Effective strategies for early detection of cognitive decline, if deployed on a large scale, would have individual and societal benefits. However, current methods are invasive or time-consuming therefore not suitable longitudinal monitoring asymptomatic individuals. For example, biological markers neuropathology associated with decline typically collected via cerebral spinal fluid, functioning is evaluated from face-to-face assessments by experts brain measures obtained using expensive, non-portable equipment. Here, we describe scalable, repeatable, relatively non-invasive comparatively inexpensive detecting the earliest decline. These approaches characterized simple data collection protocols conducted in locations outside laboratory: measurements passively, participants themselves non-experts. The analysis these is, contrast, often performed centralized location sophisticated techniques. Recent developments allow potential to be accurately detected peripheral blood samples. Advances smartphone technology facilitate unobtrusive passive speech, fine motor movement gait, that can used predict Specific processes assayed ‘gamified’ versions standard laboratory tasks, which keep users engaged across multiple test sessions. High quality regularly obtained, at-home themselves, portable electroencephalography. Although great addressing an important health challenge, there barriers overcome. Technical obstacles include need standardization interoperability hardware software. Societal challenges involve ensuring equity access new technologies, cost implementation any follow-up care, plus ethical issues.

Language: Английский

---

Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 19(5), P. 2182 - 2196

Published: Jan. 15, 2023

Abstract The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau‐associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction cortical lesions. Accumulating evidence supports role behavioral neuropsychiatric manifestations featured AD. Experimental studies even suggest that AD‐associated drives brain neuroinflammatory status contributes to progression, including exacerbation Given important pathophysiologic etiologic roles involve AD stages, there is an urgent need expand our understanding mechanisms underlying vulnerability more precisely detail clinical progression changes Here, Professional Interest Area International Society Advance Research Treatment highlights knowledge gaps about within provides recommendations priorities specific research, biomarker development, modeling, intervention. Highlights Neuromodulatory degenerate pathological stages. pathophysiology exacerbated by degeneration. symptoms dementia. Biomarkers integrity would be value‐creating dementia care. present strategic prospects disease‐modifying therapies.

Language: Английский

---

Pushing the boundaries of brain organoids to study Alzheimer’s disease

Trends in Molecular Medicine, Journal Year: 2023, Volume and Issue: 29(8), P. 659 - 672

Published: June 22, 2023

Progression of Alzheimer's disease (AD) entails deterioration or aberrant function multiple brain cell types, eventually leading to neurodegeneration and cognitive decline. Defining how complex cell-cell interactions become dysregulated in AD requires novel human cell-based vitro platforms that could recapitulate the intricate cytoarchitecture diversity brain. Brain organoids (BOs) are 3D self-organizing tissues partially resemble architecture can AD-relevant pathology. In this review, we highlight versatile applications different types BOs model pathogenesis, including amyloid-β tau aggregation, neuroinflammation, myelin breakdown, vascular dysfunction, other phenotypes, as well accelerate therapeutic development for AD.

Language: Английский

---